“no details of what the study would entail were given, and it would be conducted in the shining beacon of objectivity and impartiality that is Mexico.”

The placebo arm of a drug trial for an indication that has an established SOC is always the SOC. There’s no arguing that. Also, there was mention of a combo trial of leronlimab and remdesevir before Mexico was discussed. Remdesevir has just been given EUA around this time.